Patent application number | Description | Published |
20080312254 | Process for the Preparation of Ziprasidone - The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia. | 12-18-2008 |
20090023915 | Process for the Preparation of Faropenem - The present invention is related to processes for the preparation of faropenem. | 01-22-2009 |
20090171104 | PROCESS FOR THE PREPARATION OF ORLISTAT - The present invention provides a process for preparing orlistat (I) by alkanoylating an amino orlistat using formic acid anhydride as an alkanoylating agent to obtain orlistat substantially free of the byproduct, (S)-N-acetylleucine (1S)-1-[[(2S, 3S)-3-hexyl-4-oxo-2-oxetanyl]methyl] dodecyl ester (deformyl-N-acetyl orlistat). | 07-02-2009 |
20090203921 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF VALSARTAN - The present invention relates to processes for the preparation of intermediates of valsartan. | 08-13-2009 |
20090259047 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared. | 10-15-2009 |
20090306173 | CRYSTALLINE FORMS OF ATORVASTATIN MAGNESIUM - The present invention relates to crystalline forms of Atorvastatin magnesium and processes for their preparation. The crystalline forms of the present invention are designated as form X, form Y, form Z and form P of atorvastatin magnesium. The present invention further relates to pharmaceutical compositions comprising form X, form Y, form Z and form P of atorvastatin magnesium and method of using the crystalline forms. | 12-10-2009 |
20100004242 | PROCESS FOR THE PREPARATION OF APREPITANT - The present invention relates to a highly pure (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholin-2-yl 3,5-bis(trifluoromethyl)benzoate of Formula II, and a process for its preparation. The present invention further provides a process for preparation of Aprepitant of Formula I or pharmaceutically acceptable salt thereof, using the highly pure compound of Formula II. The present invention also provides a process for preparation of Aprepitant of Formula I or pharmaceutically acceptable salt thereof which comprises of cyclising the compound of Formula VII at elevated temperature, in the absence of solvent. | 01-07-2010 |
20100137607 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)- | 06-03-2010 |
20100179335 | PROCESS FOR THE PREPARATION OF ORLISTAT - The present invention provides a process for preparing orlistat from amino orlistat using Pivaloyl Formic Anhydride (PFA) as an alkanoylating agent. | 07-15-2010 |
20110082293 | PROCESS FOR THE PREPARATION OF STERILE DORIPENEM - The present invention relates to a process for the preparation of sterile doripenem. | 04-07-2011 |
20110086884 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared. | 04-14-2011 |
20110172201 | PROCESS FOR PREPARING A CARBAPENEM ANTIBIOTIC COMPOSITION - The present invention relates to a process for preparing a carbapenem antibiotic composition. The present invention further relates to a carbapenem antibiotic composition substantially free of degradation impurities. The present invention further relates to a polymorphic form of ertapenem mono sodium designated as Form D and its preparation. | 07-14-2011 |
20110178305 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF - The present invention relates to a process for the preparation of threo-3,4-epoxy-2-amino-1-substituted butane derivatives represented by general Formula I which comprises reacting compound of Formula III or salt thereof with an active ester of acid of Formula IV and treating the product thereof with base. The carbon atom bonded to the radical R | 07-21-2011 |
20110207933 | PROCESS FOR THE PREPARATION OF ZIPRASIDONE - The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia. | 08-25-2011 |
20120178821 | POLYMORPHIC FORM OF TOREMIFENE CITRATE AND PROCESS FOR ITS PREPARATION - The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharmaceutically acceptable salts. | 07-12-2012 |
20120184750 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL - The present invention provides an improved process for the preparation of olmesartan medoxomil, which is free of OLM-acid and has lower amount of eliminate and acetic acid impurity. | 07-19-2012 |
20120184751 | POLYMORPHIC FORM OF OLMESARTAN MEDOXOMIL - The present invention relates to a polymorphic form of olmesartan medoxomil and a process for the preparation of crystalline olmesartan medoxomil. | 07-19-2012 |
20120190849 | PROCESSES FOR THE PREPARATION OF VARDENAFIL - The present invention provides processes for the preparation of vardenafil, its pharmaceutically acceptable salts, hydrates and intermediates. | 07-26-2012 |
20120220777 | PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF LENALIDOMIDE - The present invention relates to an in-situ process for the preparation of polymorphic Form A of lenalidomide. | 08-30-2012 |
20120220783 | SALTS OF SUNITINIB - The present invention relates to salts of sunitinib and their preparation. | 08-30-2012 |
20120264789 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS - The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib. | 10-18-2012 |
20120267533 | PROCESSES FOR THE PREPARATION OF FORM I AND FORM II OF PALONOSETRON HYDROCHLORIDE - The present invention relates to processes for the preparation of Form I and Form II of palonosetron hydrochloride. The present invention further relates to a method of determining the polymorphic forms of palonosetron hydrochloride using Fourier-Transform Infra-red (FTIR) method. | 10-25-2012 |
20120271056 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM I OF L-MALIC ACID SALT OF SUNITINIB - The present invention relates to a process for the preparation of crystalline Form I of the L-malic acid salt of sunitinib. | 10-25-2012 |
20120277426 | PROCESS FOR THE PREPARATION OF CRYSTALLINE APREPITANT HAVING FORM I CONTENT - The present invention provides a process for preparation of crystalline aprepitant having not more than 15% by weight of Form I content which comprises, a) dissolving aprepitant in a suitable solvent to obtain a solution, b) cooling the solution to 10-15° C., c) optionally seeding the solution with aprepitant Form I crystals, d) adding an anti-solvent to the solution, and e) isolating crystalline aprepitant having not more than 15% by weight of Form I content. | 11-01-2012 |
20120283440 | CRYSTALLINE FORMS OF BOSENTAN SALTS AND PROCESSES FOR THEIR PREPARATION - The present invention relates to crystalline forms of bosentan salts and processes for their preparation.(FORMULA) | 11-08-2012 |
20120302749 | PROCESSES FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE FORM A AND ERLOTINIB HYDROCHLORIDE FORM B - The present invention relates to processes for the preparation of erlotinib hydrochloride Form A and erlotinib hydrochloride Form B. (I). | 11-29-2012 |
20120309842 | PROCESSES FOR THE PREPARATION OF CINACALCET - The present invention provides processes and intermediates for preparing cinacalcet base and pharmaceutically acceptable salts thereof. | 12-06-2012 |
20130005777 | SORAFENIB ETHYLSULFONATE SALT, PROCESS FOR PREPARATION AND USE - The present invention provides sorafenib ethane sulphonate, process for its preparation, pharmaceutical composition comprising sorafenib ethane sulphonate and its use for the treatment of cancer. Formula (III). | 01-03-2013 |
20130005980 | PROCESS FOR THE PREPARATION OF SORAFENIB TOSYLATE - The present invention provides a process for the preparation of sorafenib tosylate, comprising contacting sorafenib free base with p-toluenesulphonic acid in water. | 01-03-2013 |
20130123511 | PROCESS FOR THE DIRECT PREPARATION OF MALIC ACID SALT OF SUNITINIB - The present invention relates to a process for the direct preparation of malic acid salt of sunitinib. | 05-16-2013 |
20130197232 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORMS OF DEXLANSOPRAZOLE - The present invention relates to crystalline forms of dexlansoprazole designated as forms A and B, and their preparation. The present invention further relates to processes for the preparation of anhydrous dexlansoprazole and dexlansoprazole sesquihydrate using crystalline Forms A and B of dexlansoprazole. | 08-01-2013 |
20130197233 | SALTS OF DEXLANSOPRAZOLE AND THEIR PREPARATION - The present invention relates to the salts of dexlansoprazole in amorphous form. The present invention further relates to processes for the preparation of salts of dexlansoprazole. | 08-01-2013 |
20130204002 | PROCESS FOR THE PREPARATION OF DEXLANSOPRAZOLE - The present invention relates to a process for the preparation of crystalline dexlansoprazole. | 08-08-2013 |
20130210865 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE - The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N | 08-15-2013 |
20130210885 | CRYSTALLINE FORMS OF L-MALIC ACID SALT OF SUNITINIB - The present invention relates to crystalline forms of L-malic acid salt of sunitinib and its preparation. The crystalline forms of the present invention are designated as Form V and Form VI of L-malic acid salt of sunitinib. Formula (I). | 08-15-2013 |
20130245278 | PROCESS FOR THE PREPARATION OF FEBUXOSTAT - An improved and efficient process for the preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid (febuxostat) that is substantially free from amide by-product is provided. | 09-19-2013 |
20130274478 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS - The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them, and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib. | 10-17-2013 |
20140142309 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF TADALAFIL - The present invention relates to a process for the preparation of a cis-intermediate compound of Formula II | 05-22-2014 |
20140187568 | CRYSTALLINE FORMS OF BOSENTAN SALTS AND PROCESSES FOR THEIR PREPARATION - The present invention relates to crystalline forms of bosentan salts and processes for their preparation. | 07-03-2014 |
20140187569 | CRYSTALLINE FORMS OF BOSENTAN SALTS AND PROCESSES FOR THEIR PREPARATION - The present invention relates to crystalline forms of bosentan salts and processes for their preparation. | 07-03-2014 |
20140336380 | PROCESS FOR THE PREPARATION OF AGOMELATINE | 11-13-2014 |
20140343290 | PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT - The present invention relates to an improved process for the preparation of atazanavir bisulfate, an inhibitor of retroviral aspartate protease. The process of the present invention comprises conversion of 1,1-dimethylethyl[(2S,3R)-4-chloro-3-hydroxy-phenylbutan-2-yl]carbamate (Formula II) into 1-[4-(pyridine-2-yl)-phenyl]-4(S)-5 hydroxy-2-N-tert-butoxycarbonylamino-5(S)—N—(N-methoxycarbonyl-(L)-tert-leucyl)amino-6-phenyl-2-azahexane (Formula VII) without isolating intermediate compounds formed therein, followed by its subsequent conversion to atazanavir or its bisulfate salt. | 11-20-2014 |
20140350255 | PROCESS FOR THE PREPARATION OF VILAZODONE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS - The present invention relates to a process for the preparation of vilazodone or its pharmaceutically acceptable salts. The present invention further provides a crystalline form of vilazodone free base. | 11-27-2014 |
20140357870 | PROCESS FOR THE PREPARATION OF DEXLANSOPRAZOLE - The present invention relates to a process for the preparation of dexlansoprazole.xH | 12-04-2014 |
20140378472 | AMORPHOUS VILAZODONE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to amorphous vilazodone hydrochloride, its process of preparation and pharmaceutical composition thereof. | 12-25-2014 |
20150025080 | SOLID DISPERSIONS OF SITAGLIPTIN AND PROCESSES FOR THEIR PREPARATION - The present invention provides processes for the preparation of amorphous form of sitagliptin dihydrogen phosphate. It also provides a solid dispersion of sitagliptin dihydrogen phosphate, including in the amorphous form, and processes for its preparation. | 01-22-2015 |
20150031732 | FEBUXOSTAT SOLID DISPERSION - The present invention provides a solid dispersion of febuxostat, processes for its preparation, pharmaceutical compositions comprising it and its use for the chronic management of hyperuricemia in patients with gout. | 01-29-2015 |
20150073148 | PROCESS FOR THE PREPARATION OF CRYSTALLINE VILAZODONE HYDROCHLORIDE - The present invention relates to a process for the preparation of crystalline vilazodone hydrochloride. | 03-12-2015 |